Literature DB >> 8414563

The effects of etidronate disodium on progressive hearing loss from otosclerosis.

D W Kennedy1, M E Hoffer, M Holliday.   

Abstract

A 2-year prospective double-blind study was performed to evaluate the role of etidronate disodium for the treatment of progressive hearing loss in patients with otosclerosis. A pulsed dosage regimen was used during the 2-year period and the patients were followed up with otologic and audiometric examinations. Although statistically significant differences were not achieved between the study and control groups, the study did reveal a trend toward stabilization or improvement in air conduction thresholds in some frequencies (1000 and 4000 Hz) and in bone conduction thresholds at other frequencies (500, 1000, and 2000 Hz). The incidence of adverse side effects was similar in the treatment and control groups. Although no definite conclusions can be drawn from this pilot study, the findings provide encouragement for performing a larger and longer-term study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414563     DOI: 10.1177/019459989310900312

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  10 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

2.  Further hearing loss during osteoporosis treatment with etidronate.

Authors:  S Yaşil; A Cömlekçi; A Güneri
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

3.  Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

Authors:  Alicia M Quesnel; Margaret Seton; Saumil N Merchant; Christopher Halpin; Michael J McKenna
Journal:  Otol Neurotol       Date:  2012-10       Impact factor: 2.311

Review 4.  Drug delivery for treatment of inner ear disease: current state of knowledge.

Authors:  Andrew A McCall; Erin E Leary Swan; Jeffrey T Borenstein; William F Sewell; Sharon G Kujawa; Michael J McKenna
Journal:  Ear Hear       Date:  2010-04       Impact factor: 3.570

Review 5.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

6.  Response to letter to the editor by Dr. Tamas Karosi Re: "Correlation of computed tomography with histopathology in otosclerosis", Quesnel et al. Otol Neurotol 2013; 34(1):22-28.

Authors:  Alicia M Quesnel; Gul Moonis; Jason Appel; Jennifer T O'Malley; Hugh D Curtin; Michael J McKenna
Journal:  Otol Neurotol       Date:  2013-09       Impact factor: 2.311

7.  Osteoporosis, bisphosphonate use, and risk of moderate or worse hearing loss in women.

Authors:  Sharon G Curhan; Konstantina Stankovic; Christopher Halpin; Molin Wang; Roland D Eavey; Julie M Paik; Gary C Curhan
Journal:  J Am Geriatr Soc       Date:  2021-05-24       Impact factor: 5.562

8.  Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up.

Authors:  Taha A Jan; Aaron K Remenschneider; Christopher Halpin; Margaret Seton; Michael J McKenna; Alicia M Quesnel
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-09-21

Review 9.  Bisphosphonate therapy in otosclerosis: A scoping review.

Authors:  René E Zimmerer; Robert E Africa; Zack K Westenhaver; Brian J McKinnon
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-06

10.  The effectiveness of audiometric evaluation in drug treatment for otospongiosis.

Authors:  Andy de Oliveira Vicente; Hélio K Yamashita; Oswaldo Laércio Mendonça Cruz; Flavia Barros Suzuki; Norma de Oliveira Penido
Journal:  Braz J Otorhinolaryngol       Date:  2012-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.